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CHAPTER 1
Pharmacokinetic principles
Michel M.R.F. Struys, Alain Kalmar and Peter De Paepe
Introduction
Pharmacokinetics can be defi ned as the characteriza-
tion and prediction of the time course of the concen-
tration of a drug in the body. This includes the 
characteristics of drug absorption, distribution, me-
tabolism and elimination. Pharmacokinetic models 
can be used to predict the time course of this drug 
concentration. Variations in body composition or 
organ function  —  for example, in children, in preg-
nant women and fetuses in utero, in elderly popula-
tions and in patients with organ dysfunction  —  may 
affect anaesthetic drug distribution and elimination 
and therefore drug responses. In this chapter, we 
fi rst briefl y describe some of the basic concepts gov-
erning pharmacokinetics. Secondly, we focus on the 
concepts of pharmacokinetic modelling and, thirdly, 
the infl uence of various physiological changes on 
the pharmacokinetics of drugs is described.
Drug absorption
Transfer of drugs across membranes
To reach a therapeutic concentration at their site of 
action, drugs need to pass through the cell mem-
branes that separate different compartments in the 
body [1]. These membranes are 5–10 nm wide and 
are arranged in a lipid bilayer structure. This bilayer 
is present in a fl uid state embedding a mosaic of dis-
persed proteins that can penetrate both outer or 
inner leafl et of the lipid sheet [1,2]. The structure of 
the lipids in cell membranes varies widely, although 
all of them are amphipatic. The membrane lipids 
comprise phospholipids, sphingolipids and choles-
terol, and most membrane proteins are glycoproteins 
carrying carbohydrates on their outer surface. In the 
same way, some phospholipids are glycolipids. The 
molecules in cell membranes are orientated in such a 
way that non-polar elements are confi ned to the core 
and polar elements are exposed on either side. 
The hydrophobic core favours the crossing of lipid-
soluble molecules and hampers the movement of 
water-soluble ones across the cell membranes [2]. 
The nature of the compartmentalization by mem-
branes strongly depends on the specifi c structure of 
the barrier in different tissues. In some tissues, such 
as the gastrointestinal tract, the lining cells are close-
ly connected. In other tissues, such as the glomerulus 
of the kidney, there are gaps between cells allowing 
fi ltration [1]. The permeability of vascular endothe-
lium throughout the body also varies. There are gaps 
between endothelial cells of the capillary wall, but in 
some tissues, such as the central nervous system 
(CNS), there are tight junctions between the en-
dothelial cells of the capillaries forming the blood–
brain barrier [1,3].
Theoretically, drugs can move across cell mem-
branes by passive mechanisms or by active processes 
[4]. Lipophylic drugs cross cell membranes very 
easily by simple diffusion. The rate of diffusion 
across the membrane depends on the concentration 
gradient, the size of the molecules (smaller molecules 
diffuse more easily than large ones), the lipid solubil-
ity, membrane properties such as the membrane 
area and thickness, and the diffusion coeffi cient. 
Drugs in a charged, ionized form cannot pass through 
membranes by simple diffusion; only the uncharged 
fraction can [1]. The Henderson–Hasselbalch equa-
tion makes it possible to calculate the uncharged 
fraction of a drug, given its pKa and the ambient pH. 
From:
pH = pKa + log base/acid (1)
For acidic drugs, this results in:
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pH = pKa + 
 log ionized concentration/
unionized concentration (2)
For basic drugs, this results in:
pH = pKa + 
 log unionized concentration/
ionized concentration (3)
Ionization is not only important in determining 
the rate of which a compound can move across 
a membrane, it is also important in determining 
the partition of a drug between compartments with a 
different ambient pH. Diffusion of water-soluble 
drugs is restricted by passage through aqueous pores 
that span the cell membrane. However, these ch an-
nels are too small to let most drugs pass through 
them. Endothelial membranes in the capillaries 
can have larger pores allowing bulky molecules to 
pass through [4]. Diffusion can also be facilitated 
by carrier-mediated mechanisms that operate 
along a concentration gradient without making 
use of an energy source. This is called ‘facilitated 
diffusion’ [1].
Active transfer mechanisms require energy. The 
energy can be supplied by the hydrolysis of adeno-
sine triphosphate (ATP) directly, as for instance in 
the case of Na+/K+ ATPase, or indirectly by the cou-
pling of the passive transfer of one compound along 
its ionic gradient with the movement of another 
molecule against its concentration gradient [3]. An 
example of such a transport system is the absorption 
of amino acids from the small bowel lumen into in-
testinal cells [1]. This transfer is achieved by a cou-
pling with Na+ diffusion that occurs down its 
electrochemical gradient. Maintenance of the latter 
requires energy and ultimately depends on the Na+/
K+ ATPase system [3].
Pinocytosis transports large molecules [3]. In this 
process a part of the cell membrane is invaginated to 
form a vesicle, which engulfs extracellular material, 
and is removed via exocytotic mechanisms.
Drug administration techniques 
in anaesthesia
There are many ways in which a drug can be given. 
Although most drugs are given orally, in anaesthesia 
many drugs are administered intravenously. Be-
cause absorption is bypassed, drug action is very fast 
by this route. However, for all other routes of drug 
administration, the drug must be absorbed from the 
site of application before being carried in the circula-
tion to its site of action.
Intramuscular or 
subcutaneous administration
Many factors affect the rate of absorption after intra-
muscular or subcutaneous injection. The molecular 
weight of the compound, the vehicle in which the 
drug is dissolved, the volume that is given and, last 
but not least, the local perfusion of the muscle and fat 
tissue are important [5]. Some drugs are absorbed 
very easily, but for others the absorption is poor or 
unpredictable (e.g. diazepam) [6]. After the injec-
tion of water-soluble drugs, the plasma level can in-
crease rapidly, because these compounds enter the 
circulation very fast. This is especially true for drugs 
with low molecular weight, which can reach the sys-
temic circulation by entering the capillaries directly 
[5]. The use of vasoconstrictors or vasodilators, as 
well as individual patient haemodynamics, can also 
markedly infl uence the rate of absorption.
Inhalation
Depending on the particle size, inhaled drugs will 
mainly reach airway mucosa from the larynx to the 
bronchioles, creating local effects, or reach the alve-
olus, allowing largely systemic effects. However, sys-
temic absorption may still occur in both cases [5]. 
Volatile molecules readily reach the alveolar space 
and can enter the systemic circulation within sec-
onds. The rate of absorption of volatile anaesthetics is 
determined by adequacy of pulmonary ventilation, 
cardiac output, inspired concentration and anaes-
thetic solubility [7].
Epidural, intrathecal and 
perineural administration
Epidural, intrathecal or perineural administration of 
drugs is used for providing regional analgesia and an-
aesthesia. The onset time depends on the concentra-
tion of unionized local anaesthetic around the axon. 
Because local anaesthetics are bases, adding sodium 
bicarbonate reduces onset time in epidural solutions. 
Addition of a vasoconstrictor increases the duration 
of the block [1].
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Oral administration
Multiple factors are involved in the absorption of the 
drug from the gastrointestinal tract to the systemic 
circulation. First-pass metabolism, unpredictable 
pharmacokinetics and a latent period before maxi-
mal concentration in plasma make this route unsuit-
able for many anaesthetics [8].
Rectal administration
The rectal blood fl ow partly drains directly into the 
systemic circulation, avoiding fi rst-pass metabolism, 
although absorption is unpredictable [1].
Sublingual, buccal and 
nasal administration
While permitting very fast absorption of certain 
drugs, these routes directly drain into the systemic 
circulation, avoiding fi rst-pass effect [5].
Bioavailability
Bioavailability is generally defi ned as the fraction of 
an extravascularly administered dose that reaches 
the systemic circulation [5]. An orally administered 
dose is only partially absorbed from the gut and par-
tially metabolized in the gut wall and liver before 
reaching the systemic circulation.
Drug absorption and fi rst-pass effect
Before the drug can cross the mucosal membranes 
after oral intake, the tablets must disintegrate and 
dissolve. Pharmaceutical factors such as chemical 
formulation, particle size, coatings or the inclusion 
of inert fi lters infl uence this dissolution process [8]. 
Because most drugs only pass the lipid membranes 
in their unionized form, the regional pH greatly in-
fl uences absorption. Consequently, acidic drugs 
would mainly be absorbed in the stomach, but the 
large surface area and anatomical properties of 
the small intestine make this the main absorption 
site for all drugs [4]. The speed of gastric emptying, 
simultaneous intake of other drugs or food and patho-
logical conditions also infl uence the speed and 
degree of drug absorption [1]. Before reaching the 
systemic circulation, the drugs need to pass through 
the intestinal mucosa and the liver [8]. Metabolism 
of the drug may occur in the gut wall or by the liver, 
further reducing the amount that reaches the 
target organ.
Drug distribution
The basic pharmacokinetic parameter to describe 
drug distribution is the apparent volume of distribu-
tion (Vd), calculated as:
Vd = amount of drug/concentration (4)
It must be noted, however, that this has been simpli-
fi ed by assuming that the drug is administered into a 
single, well-mixed compartment. If the drug remains 
unbound in the plasma and does not distribute into 
other tissues, the Vd would be the same as the plasma 
volume. However, most drugs leave the plasma 
and distribute into and bind to other tissues. Drug 
distribution throughout the body depends largely on 
organ blood fl ow and physicochemical properties 
of the drug, such as lipid solubility and protein 
binding.
Blood fl ow
Shortly after a drug enters the systemic circulation, 
tissue concentrations rise in the more highly per-
fused organs, such as the brain and liver. Organs with 
lower blood fl ow will take longer to equilibrate, and, 
in some cases, this may take several hours or even 
days [4].
Lipid solubility
After passing into the extravascular space, water-
soluble drugs are mostly limited to the extracellular 
fl uid, while lipid-soluble drugs easily cross cell mem-
branes and can accumulate in certain tissues. For 
instance, lipophilic drugs such as thiopental may ac-
cumulate in fat, and be redistributed to other organs 
afterwards, prolonging the duration of drug action 
[4]. This indicates that drug distribution throughout 
the body depends largely on physicochemical 
properties.
Protein binding
In plasma, many drugs are bound to a variable 
degree to plasma proteins and, because only free 
unbound drug is able to move across capillary 
membranes, this protein-bound fraction cannot be 
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regarded as pharmacologically active [4,9]. The 
plasma proteins have multiple binding sites and the 
amount of drug bound depends on its total concen-
tration, the competition for binding by other com-
pounds for the same binding sites, the concentration 
of protein and the affi nity between drug and protein 
[10]. As a rule, neutral and acidic drugs bind to albu-
min and basic drugs bind also to α1-acid glycoprotein 
and lipoproteins [1]. Plasma protein binding is par-
ticularly important for drugs that occupy a large por-
tion of the available binding sites at therapeutic 
concentrations. With these drugs, a small increase in 
the bound fraction can increase the unbound frac-
tion out of proportion [1,6].
Special membranes
Blood–brain barrier
Contrary to most tissues, where capillary membranes 
are freely permeable, cerebral capillaries form tight 
junctions, restricting free diffusion of drugs into the 
cerebral extracellular fl uid. Besides this structural 
barrier, astrocytes form a metabolic or enzymatic 
blood–brain barrier that neutralize certain agents be-
fore they reach the CNS. Penetration of drugs into 
the brain depends on ionization, molecular weight, 
lipid solubility and protein-binding [5]. However, 
peptides such as bradykinin and enkephalins and 
certain conditions such as infl ammation can 
increase the blood–brain barrier permeability, allow-
ing normally impermeable substances to enter the 
brain [6].
Placental barrier
Most low molecular weight, lipid-soluble drugs can 
easily cross the placental barrier while large molecu-
lar weight or polar molecules cannot [8]. Differences 
in fetal blood pH, placental blood fl ow, protein bind-
ing and fetal metabolism infl uence fetal free drug 
levels [1]. As a rule, drugs that affect the CNS  —  and 
consequently pass the blood–brain barrier  —  can also 
cross the placenta [8].
Drug metabolism
After administration, most drugs (certainly if they 
are lipid-soluble) have to be metabolized before they 
can leave the body. In most cases metabolism 
reduces the activity of a drug, but in some cases met-
abolic conversion of a drug may increase or only par-
tially decrease its activity. Generally, metabolism 
results in a more water-soluble molecule that can be 
excreted more easily. The main organ for drug me-
tabolism is the liver [8], but processes also take place 
in the gut, plasma, gastric mucosa, lung or other or-
gans [1]. Metabolism consists of two phases.
Phase I
In phase I, molecules are chemically activated to pre-
pare for possible phase II reaction [5]. Three types of 
enzymatic reactions may occur: oxidation, reduction 
and hydrolysis.
Oxidation
Many oxidative reactions take place in the endoplas-
matic reticulum of the liver, the microsomes, and are 
catalysed by the cytochrome P450 system. The P450 
superfamily comprises more than 30 different isoen-
zymes in humans. However, the majority of P450s 
involved in drug metabolism belong to three distinct 
families: CYP1, CYP2 and CYP3. These are essential 
in the elimination of drugs as well as in the synthesis 
or metabolism of endogenous compounds. Mono-
amines are metabolized by monoamine oxidase in 
the mitochondria. Alcohol dehydrogenase is local-
ized in the cytoplasm.
Reduction
These reactions typically take place in the hepatic en-
doplasmic reticulum and cell cytoplasm. As in oxida-
tion, the cytochrome P450 system is responsible for 
many reduction reactions [8].
Hydrolysis
Esterases are active in plasma as well as in the liver. 
They are able to hydrolyse an ester to the alcohols 
and the carboxylic acid.
Phase II
Conjugation or synthesis
These reactions include glucuronidation, sulpha-
tion, acetylation, methylation or glycination. This 
generally increases the water solubility, favouring 
renal or biliary excretion, and most of these reactions 
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take place in the liver microsomes, but the lung is 
also involved [1].
Drug excretion
Either directly or after biotransformation, drugs are 
eliminated out of the body in urine or bile. Small 
amounts are also excreted in saliva, sweat and milk, 
but this is usually of little quantitative signifi cance 
[5]. Small molecules are mainly excreted in urine; 
high molecular weight molecules (>400–500 Da) are 
preferentially eliminated in bile.
Renal excretion
Three processes account for renal drug excretion: 
fi ltration, secretion and diffusion.
Glomerular fi ltration
Glomerular fi ltration is a passive process involving 
fi ltration of mainly unbound fraction of water-
soluble molecules. Large or highly protein-bound 
molecules will not cross the glomerular membrane 
[8].
Tubular secretion
Tubular secretion is an active carrier-mediated se-
cretion that may take place against a concentration 
gradient. For some drugs, complete clearance may be 
achieved in a single renal circulation [8].
Tubular diffusion
In the distal renal tube, depending on urine pH, im-
portant passive diffusion may take place between the 
urine and the plasma. This mechanism is restricted to 
substances capable of crossing tubular cell mem-
branes and can result in marked reabsorption of ex-
creted drugs. In addition, the elimination of certain 
drugs can be increased by alterations in urine pH; 
after diffusion of the non-ionized fraction of certain 
basic drugs from the relatively alkaline plasma 
to the acid urine, they are trapped as cations and 
excreted [8].
Biliary excretion
Hepatocytes actively transport high molecular 
weight molecules, such as the steroid-based muscle 
relaxants, to the bile. This is a saturable process which 
can be inhibited by other drugs. Active transport may 
result in signifi cant concentration of certain drugs, 
up to 100 times the plasma level [5]. Some drugs 
require conjugation, but others are excreted unchan-
g ed in bile. Conjugated drugs excreted in the bile 
may be subsequently hydrolysed by bacteria in the 
gut and reabsorbed, increasing their biological half-
life [1], a process called enterohepatic recirculation.
Drug clearance
The two main organs responsible for drug excretion 
are the liver and kidneys. Clearance is defi ned as the 
volume of plasma from which a drug is completely 
removed per time unit. Many drugs are metabolized 
by the liver and although their metabolites may stay 
in the blood for some time before actual excretion, 
they often have no or little residual pharmacological 
effect. On the other hand, a drug may be removed 
from the body both by urinary excretion of un-
changed drug and by hepatic metabolism.
Clearance values can be considered as the sum of 
the clearances by the various organs involved for a 
certain drug:
Cl = ClR + ClH + CLX (5)
whereby ClR is renal clearance, ClH is hepatic clear-
ance and CLX is clearance by other routes. The clear-
ance of most drugs is mainly dependent on the 
liver, either by hepatic metabolism and/or biliary 
excretion [8].
The pharmacokinetic concept of hepatic clearance 
takes into consideration that the drug is transported 
to the liver by the portal vein and the hepatic artery 
and leaves the organ by the hepatic vein [11]. It dif-
fuses from plasma water to reach the metabolic en-
zymes. There are at least three major parameters to 
consider in quantifying drug elimination by the liver: 
blood fl ow through the organ (Q), which refl ects 
transport to the liver; free fraction of drug in blood 
(fu), which affects access of drug to the enzymes; and 
intrinsic ability of the hepatic enzymes to metabolize 
the drug, expressed as intrinsic clearance (Clint). In-
trinsic clearance is the ability of the liver to remove 
drug in the absence of fl ow limitations and blood 
binding. Taking into account these three parameters, 
the hepatic clearance can be expressed by:
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It is obvious that the hepatic clearance cannot be 
larger than the total volume of blood reaching the 
liver per unit time (i.e. the liver blood fl ow Q). The 
ratio of the hepatic clearance of a drug to the hepatic 
blood fl ow is called the extraction ratio of the drug 
(E), which can be expressed as:
E
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C
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a
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where Ca is the concentration in the mixed portal ve-
nous and hepatic arterial blood and Cv is the hepatic 
venous blood concentration. The value of the extrac-
tion ratio can vary between 0 and 1. It is 0 when 
fu· Clint is zero (i.e. when the drug is not metabolized 
in the liver); it is 1 when the hepatic clearance equals 
hepatic blood fl ow (approximately 1.5 L/min in 
humans).
The extraction ratio can be generally classifi ed 
as high (>0.7), intermediate (0.3–0.7) or low (<0.3) 
according to the fraction of drug removed during 
one pass through the liver. The effect of critical ill-
ness on hepatic clearance depends on these extrac-
tion characteristics of the drug as explained below 
(see p. 18). Table 1.1 lists the hepatic extraction ratio 
in humans for some sedative and analgesic drugs.
High extraction drugs
Drugs with a high hepatic extraction have a high in-
trinsic hepatic metabolizing capacity (fu·Clint >> Q) 
and are rapidly and extensively cleared by the liver 
from the blood. Their clearance depends primarily 
on hepatic blood fl ow, and binding to blood compo-
nents is not an obstacle for extraction; the extraction 
is said to be non-restrictive or blood fl ow dependent. 
This results in a simplifi cation of equation 6:
Cl ≈ Q (8)
Changes in protein binding will have no infl uence 
on the clearance of high extraction drugs. The 
importance of changes in protein binding must 
also be assessed by evaluating the infl uence on 
the drug concentrations, particularly on the free 
drug concentrations as they determine the drug ef-
fect. This is made clear by the following equations, 
which illustrate the relationship between total 
(CSS) and unbound (CSS,u) drug concentrations at 
steady state, and Cl following intravenous drug 
administration:
C
R
Cl
SS =
0  (9)
and
C
f R
Cl
SS u
u
, =
⋅ 0  (10)
where R0 represents the rate of drug input. Because 
Cl ≈ Q (equation 8) for high extraction drugs, one can 
substitute Q for Cl in equations 9 and 10. It is appar-
ent that CSS is not affected by changes in protein 
binding, whereas CSS,uchanges directly with fu. The 
latter implies that for high extraction drugs, changes 
in free drug fraction may result in alterations in drug 
effect.
Low extraction drugs
Drugs with a low hepatic extraction have a low 
intrinsic hepatic metabolizing capacity (fu · Clint << 
Q) and are extracted less avidly and incompletely 
from hepatic blood. Their clearance is relatively in-
dependent of hepatic blood fl ow, and is primarily de-
termined by the intrinsic metabolizing capacity of 
the liver and by the free drug fraction; the extraction 
Table 1.1 Some example drugs with various hepatic 
extraction ratios (ER).
Low ER Intermediate ER High ER
(ER < 0.3) (ER 0.3–0.7) (ER > 0.7)
Diazepam Alfentanil Fentanyl
Lorazepam Chlorpromazine Flumazenil
Methadone Diphenhydramine Ketamine
Pentobarbital Droperidol Morphine
Chlordiazepoxide Etomidate Nalmefene
 Haloperidol Naloxone
 Hydromorphone Propofol
 Midazolam Sufentanil
 Pethidine
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is said to be restrictive or capacity limited. This results 
in a simplifi cation of equation 6:
Cl ≈ fu · Clint (11)
Changes in free fraction may occur during critical 
illness and will result in alterations of clearance of 
low extraction drugs. When substituting equation 
11 into equations 9 and 10, it is clear that for low ex-
traction drugs changes in protein binding are in-
versely related to CSS, but have no effect on CSS,u.
Intermediate extraction drugs
The clearance of drugs with intermediate extraction 
is dependent on hepatic blood fl ow, the intrinsic 
metabolizing capacity of the liver and free drug 
fraction.
Pharmacokinetic analysis of the 
time course of the drug 
concentration
Pharmacokinetic analysis in the 
individual patient
The study of the time course of drug concentrations 
in plasma, urine and other sampled sites has been 
helped by the development of sensitive analytic 
techniques such as high performance liquid chroma-
tography (HPLC), mass spectrometry and radioim-
munoassay. Changes in measured drug concentra-
tion in relation to time are used to derive pharma-
cokinetic constants that describe the behaviour of 
drugs in the body. The two most important pharma-
cokinetic constants to describe the characteristics 
of a drug are the volume of distribution (Vd) and 
clearance (Cl). The volume of distribution represents 
the apparent volume available in the body from the 
distribution of the drug. The clearance represents 
the body’s ability to remove drug from the blood or 
plasma. Both Vd and Cl can be determined from a 
decline in their plasma concentration after drug 
administration.
Two methods to determine Vd and Cl are discussed 
in this chapter. Although model-independent analy-
sis still represents the gold standard by which the es-
timates of other techniques should be compared, this 
approach does not offer suffi cient information to 
facilitate the development of rational drug dosing 
guidelines. Therefore, compartmental or physiologi-
cal model-dependent analysis is mandatory.
Model-independent 
pharmacokinetic analysis
Model-independent pharmacokinetics represents a 
straightforward approach based purely on mathe-
matical descriptions of blood or plasma profi les of 
drugs or metabolites without invoking a particular 
model. In many situations, such as during drug de-
velopment, it is suffi cient to characterize plasma pro-
fi les in terms of maximum plasma concentration 
levels, Cmax, time of maximum level, tmax, and area 
under the plasma curve, AUC. These parameters can 
be obtained by simple inspection of the plasma or 
blood concentration of the drug versus time, as seen 
in Fig. 1.1. From AUC, one can determine the clear-
ance and volume of distribution [12].
The AUC, representing the change in concentra-
tion (C) during time (t) (starting at the moment of 
drug administration) can be calculated by using the 
integral:
AUC C t dt= ⋅
∞∫ ( )
0
.
 (12)
In practice, the AUC can be estimated using the 
‘trapezoidal rule’. Because the total amount of drug 
eliminated between the moment of drug administra-
tion and infi nity must be equal to the dose, we can 
rewrite equation 12 as follows:
Dose = CL · AUC (13)
From equation 13, we can calculate the drug clear-
ance (CL) as:
CL = Dose/AUC  (14)
The second basic pharmacokinetic parameter, vol-
ume of distribution (Vd), can also be determined as:
Vd = CL · MRT (15)
Whereby MRT stands for the ‘mean residence time’, 
calculated as the ratio between the total area under 
the fi rst moment of the plasma concentration–time 
curve (i.e. the area under the plasma concentration × 
time versus time curve, extrapolated to infi nity) or 
AUMC and the AUC:
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MRT = AUMC/AUC (16)
It has to be stated that the Vd calculated here is the 
apparent volume of distribution. If the drug remains 
unbound in the plasma and does not distribute into 
other tissues, the Vd would be equal to the plasma 
volume. As most drugs distribute through extravas-
cular sites in the body and bind to other tissues, the 
apparent Vd might be much larger than the whole 
body volume. In contrast, the initial volume is 
usually reported, which, for an intravenous bolus 
dose, is determined using equation 16:
Vd = Amount/Concentration = dose/C0 (17)
whereby the drug concentration is ‘back-
extrapolated’ to time zero (C0).
Model-dependent 
pharmacokinetic analysis
Two approaches towards model dependent pharma-
cokinetic analysis are discussed: compartmental and 
physiological models. In the compartmental model, the 
body is assumed to be made up of one or more com-
partments. These compartments might be special or 
chemical in nature but, in most cases, the compart-
ment is used to represent a body volume or group of 
similar tissues or fl uids into which a drug is dis-
tributed. In the physiological model approach, phar-
macokinetic modelling is based on known anatomical 
or physiological values and the modelling of drug 
movement is based on the fl ow rates through partic-
ular organs or tissues and experimentally deter-
mined blood-tissue concentration ratios. Although 
compartmental models are dramatically simplifying 
the ‘pharmacokinetic reality’ and physiological 
models might be a more realistic approximation, 
compartmental models are often used clinically in 
anaesthesia to predict the plasma concentration of 
various drugs (e.g. propofol, opioids). Since the in-
troduction of computer-controlled drug delivery 
systems into clinical practice (so-called target con-
trolled infusion devices), it is crucial to understand 
the underlying theoretical concepts of compartmen-
tal models. Therefore, the development of these 
models is explained in more detail below.
Compartmental models
The simplest pharmacokinetic model is the ‘one-
compartment model’ with a single volume (V) and 
clearance (CL), as shown in Fig. 1.2. Clearance is 
calculated as k10 · V, whereby k10 is the rate constant 
for drug elimination. Although almost none of the 
drugs used in anaesthesia can be accurately charac-
terized by the one-compartment model, it allows 
the introduction of some mathematical concepts. 
There are two forms of processes: zero-order and 
fi rst-order. A zero-order process is one that happens 
at a constant rate. The mathematics of the rate of 
change (dx/dt) is simple:
Constant rate of change = k = dx/dt (18)
where x is the amount of drug and t is time.
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Figure 1.1 Time course of the plasma 
concentration of a drug after bolus 
injection. AUC, area under the curve; 
Cmax, maximum plasma concentration; 
tmax, time at Cmax.
WEB_01.indd   10 7/5/2006   10:10:34 AM
Pharmacokinetic principles   11 
If the value of x at time t is needed, x(t), it is found 
as the integral of the equation 18 from time 0 to 
time t:
x(t) = x0 + k · t (19)
where x0 is the value of x at t = t0. This is a straight 
line with a slope of k and an intercept of x0.
A fi rst-order process is much more complex. The 
rate of change for a fi rst-order process is:
dx/dt = k · x (20)
where the units of k are simply 1/time. If a value of x 
at time t is needed, x(t), it can be found as the integral 
of the equation 20 from time 0 to time t:
x(t) = x0 · e
 −kt (21)
By using the equation C0 = x0/V, where C0 is 
the concentration at time 0, x0 is the initial dose of 
drug and V is the volume of the compartment, the 
plasma concentrations over time after an IV bolus 
of drug are then described by:
C(t) = C0 · e
 −kt (22)
This is the commonly used expression relating con-
centration to time and initial plasma concentration 
and the rate constants. It defi nes the ‘concentration 
over time’ curve for the one-compartment model 
and has a log-linear shape. The one-compartment 
model is frequently used in pharmacology to describe 
the pharmacokinetics of drugs. It demonstrates the 
concepts of volumes, clearances and rate constants. 
In this model, no distribution phenomenon occurs. 
Unfortunately, none of the intravenous hypnotic 
anaesthetic drugs used in clinical anaesthesia can be 
characterized accurately by a one-compartment 
model because of their distribution into and out of 
the peripheral tissues. Therefore, it is necessary to 
extend this one-compartment model to a multicom-
partmental one.
Several multicompartment models are described 
in the literature [13,14]. Although a two-
compartmental model is used commonly in general 
drug research, the most popular one in anaesthesia is 
the three-compartment mammalian model, as 
shown in Fig. 1.3. In anaesthesia, all clinically used, 
target controlled, infusion techniques and pharma-
cokinetic computer simulations are based on this 
model.
The fundamental variables of the compartment 
model are the volume of distribution (central, 
rapidly and slowly equilibrating peripheral volumes) 
and the clearances (systemic, rapid and slow inter-
compartmental). As shown in Fig. 1.3, the drug is in-
jected into and eliminated either by metabolism or 
renal excretion from this central compartment (com-
partment 1). The drug is quickly distributed into a 
rapidly equilibrating peripheral compartment (com-
partment 2) and this compartment quickly reaches 
equilibration with the central compartment. The 
drug is distributed more slowly into a third compart-
ment (compartment 3). The sum of the compart-
mental volumes is the apparent volume of distribution 
during steady-state (VdSS) and is proportionally con-
stant, relating the plasma drug concentration at 
steady-state to the amount of drug in the body [13].
Micro-rate constants, expressed as kij, defi ne the 
rate of drug transfer from compartment i to compart-
ment j. Compartment 0 is a compartment outside 
the model, so k10 is the micro-rate constant for 
those processes acting through biotransformation or 
elimination that irreversibly remove drug from the 
central compartment (compartment 1). The inter-
compartmental micro-rate constants (k12, k21, etc.) 
describe the exchange of drug between the central 
and peripheral compartments. Each compartment 
has at least two micro-rate constants: one for drug 
entry and one for drug exit. The differential 
Drug administration
Volume of distribution
k10
I
Figure 1.2 The one-compartment pharmacokinetic 
model.
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equations describing the rate of change for the 
amount of drugs in compartments 1, 2 and 3, follow 
directly from the micro-rate constants (note the sim-
ilarity to the one-compartment model).
For example, for a three-compartment model, the 
differential equations are:
dx1/dt = I + x2k21 + x3k31 − x1k10 − x1k12 − x1k13
 = I + x2k21+ x3k31 − x1(k10+ k12+ k13) (23)
dx2/dt = x1k12 − x2k21 (24)
dx3/dt = x1k13 − x3k31 (25)
where I is the rate of drug input, x is the amount of 
drug for a specifi c compartment and k is a micro-rate 
constant. Each of the above equations can be 
solved and the complete solution can be found in the 
literature [14].
How may we explore into how many compart-
ments the pharmacokinetic behaviour of a specifi c 
drug fi ts? This can be done by taking plasma samples 
at specifi c time points after a bolus injection and de-
picting the results in a log (plasma concentration) 
over time graph, as shown in Fig. 1.4.
Three distinct phases can be distinguished. There 
is a rapid ‘distribution’ phase (solid line) that begins 
immediately after the bolus injection. This phase is 
characterized by very rapidly equilibrating tissues. 
There often is a slower second distribution phase (dashed 
line) that is characterized by a movement of the 
drug into more slowly equilibrating tissues and a 
return of the drug from the most rapidly equilibrat-
ing tissues (i.e. those that reached equilibrium with 
the plasma during phase I). The terminal phase 
(dotted line) is a straight line when plotted on a 
semi-logarithmic graph. The terminal phase often is 
called the elimination phase because the primary 
mechanism for decreasing drug concentration dur-
ing the terminal phase is its elimination from the 
body [13].
Mathematically, a decreasing curve with a con-
stant slope can be described, as in equation 21. This 
is for a one-compartmental model. Curves that 
continuously decrease over time, with a contin-
Drug administration
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Figure 1.3 The three-compartment 
pharmacokinetic model.
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Figure 1.4 The triexponential curve 
representing the time course of a drug 
plasma concentration after intravenous 
injection. Each exponential term 
accounts for a portion of the curve. The 
individual lines associated with each 
exponential term are also shown. The 
triexponential curve represents the 
algebraic sum of the individual 
exponential functions. Solid, dashed 
and dotted lines are used to show how 
each exponential relates to different 
portions of the full curve.
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uously declining slope (Fig. 1.4), can be described 
by the sum of multiple equations 21, one for each 
compartment. This is the sum of exponentials 
describing the decrease of plasma concentration 
over time:
C(t) = A e−αt + B e−βt + C e−γ t (26)
where t is the time after injection of the bolus, C(t) is 
the drug concentration after a bolus dose, and A, α, 
B, β, C and γ are variables of a pharmacokinetic 
model. A, B, and C are called coeffi cients and express 
an equivalent of compartmental concentrations. At 
time 0,
C0 = A + B + C (27)
α, β and γ are called exponents (sometimes called 
hybrid rate constants). These exponents express 
the slope of each exponential decay, as shown in 
Fig. 1.4.
Equation 26 can be transformed mathematically 
from the exponential form to the ‘compartmental’ 
form (the form using the micro-rate constants). For 
the three-compartment mammillary model, this in-
terconversion between the exponential form (equa-
tion 26) and the micro-rate constant form (equations 
23–25) becomes exceedingly complex as more expo-
nents are added. This is because every exponent is a 
function of every micro-rate constant and vice versa. 
It is not the purpose of this chapter to explain and 
solve all the equations. The complete solution of the 
three-compartment model can be found in the liter-
ature [13,14].
Front-end kinetics to optimize 
compartmental models
In a classical multicompartmental mammalian 
pharmacokinetic model, intravenously adminis-
tered drugs are assumed to mix instantaneously in 
an initial distribution volume (Vc) that includes, at a 
minimum, the intravascular space. In reality, the 
volume of distribution of a drug expands with a time 
course dependent on the physiological environment 
and chemical characteristics of the drug. As a result, 
the estimate of Vc will be smaller when earlier blood 
sampling is applied. Nonetheless, conventional 
pharmacokinetic models overestimate because they 
ignore the complexity of intravenous mixing [15].
Recirculatory multicompartmental pharmacoki-
netic modelling can be applied to describe drug 
disposition from the moment of rapid intravenous 
injection. These models retain the relative simplicity 
of mammalian models, but incorporate descriptions 
of key physiological processes that have emerged as 
important determinants of intravenously injected 
drug disposition. In the fi t of the recirculatory model 
to the data, the concentration at time zero is zero and 
there is a delay between the time the drug is adminis-
tered and the time the drug appears at the sampling 
site. This model fi ts the early arterial concentrations 
of samples obtained soon after rapid intravenous 
input. Pulmonary uptake, injection rate, intravascu-
lar mixing and the infl uence of the cardiac output on 
this phenomenon are taken into account. First appli-
cations of these recirculatory multicompartmental 
models have recently been published [15,16].
Non-linear compartmental models
When drug behaviour is studied by pharmacokinetic 
models, it is mostly assumed that distribution and 
elimination are fi rst-order processes resulting in a 
linear relationship between concentration at any 
time and dose. This assumption is only correct if 
elimination and transport processes never become 
saturated. When saturation occurs (e.g. saturation of 
an enzyme system), the rate of drug elimination 
reaches a maximum and becomes concentration in-
dependent [12]. For a single non-linear compart-
mental model, the elimination rate (ER) can be 
described as:
ER
V C t
K C t
n
m
=
+
u
u
)(
( )
 (28)
where Cu(t) is the concentration of the unbound drug 
at time t and Km is the Michaelis–Menten constant, 
which is the concentration at which the rate is half 
maximum, Vm. When Cu<< Km, then the process is 
not saturated and the rate is dependent on the con-
centration, described as:
ER
V
K
C t Cl C tn
m
= ⋅ = ⋅u u( ) ( )  (29)
In contrast, when Cu is much greater than Km, satura-
tion occurs, the elimination rate approaches Vm and 
is concentration independent (ER = Vm).
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Physiological models
The description of physiological drug models de-
pends on the interpretation of drug distribution in 
terms of anatomical or physiological spaces, which 
have defi ned volumes, perfusion characteristics and 
partition coeffi cients. Individual compartments may 
have ‘fl ow-limited’ or ‘membrane-limited’ charac-
teristics (depending on whether blood fl ow or trans-
membrane transport is the limiting factor governing 
drug uptake). This means that the time course of 
drug or metabolite levels in the various ‘physiologi-
cal’ organs or compartments is calculated using blood 
fl ow rate through each particular region, diffusion of 
the drug between blood and tissue, and the relative 
affi nity of drug for blood and the various tissues and 
organs [17].
These complex physiologically based pharmacoki-
netic models have been used to describe the disposi-
tion of volatile anaesthetics [18]. For intravenously 
administered agents, however, their application has 
been sporadic because of the large number of param-
eters involved in the studies to determine the 
models. Therefore, their application is justifi ed only 
when detailed mechanisms of drug metabolism or 
excretion by liver, kidney, lung or other organs is re-
quired or when specifi c tissue localization should be 
depicted (e.g. anticancer drugs).
Connecting pharmacokinetics 
and dynamics
The time course of drug concentration, defi ned as 
the pharmacokinetics of the drug, cannot in itself 
predict the time course or magnitude of drug effect. 
In clinical practice, a delay is frequently observed be-
tween the moment of peak plasma concentration, 
peak concentration at the effect site and peak drug 
effect. This delay occurs when the plasma is not the 
site of drug action, but only a means of transport, 
and is called counterclockwise or anticlockwise 
hysteresis. Drugs exert their biological effect at the 
‘biophase’, also called the effect site, which is the im-
mediate area where the drug acts on the body, and 
includes membranes, receptors and enzymes. The 
study of the concentration–effect relationship is 
called pharmacodynamics and is covered elsewhere 
in this book. Problems resulting from temporal dis-
equilibrium (hysteresis) can be overcome by using 
the concept of the effect compartment model [19,20] 
in which drug response is modelled against drug con-
centration in a hypothetical effect compartment. 
The concentration of the drug in this theoretical 
compartment is directly related to the measured 
drug effect.
The effect compartment is an additional compart-
ment linked to the central compartment of the mam-
millary pharmacokinetic model, as shown in Fig. 1.5. 
The effect compartment receives drug from the cen-
tral compartment by a fi rst-order process, expressed 
by a fi rst-order rate constant, ke1. The actual mass of 
drug reaching the effect compartment is negligible. It 
is assumed that the effect compartment kinetics do 
not affect the pharmacokinetic model. Given these 
assumptions, the effect compartment can be consid-
ered a compartmental model with an input defi ned 
by a fi rst-order rate constant (ke1) and a fi rst-order 
rate constant defi ning the output (ke0). The time to 
reach a steady-state concentration in this effect com-
partment is dependent on the elimination from the 
effect compartment. A clarifi cation of this statement 
is found in equation 30
Ce = CSSe (1 − e
 −ke0t) (30)
The term Ce defi nes the drug concentration in the 
effect compartment, CSSe refers to the concentration 
at steady-state or the concentration that will be 
reached in the effect compartment after equilibra-
tion with the concentration in the central compart-
ment of the pharmacokinetic model. The time to 
reach a steady-state is solely dependent on the ke0. 
This rate constant can precisely characterize the tem-
poral aspect of equilibration between plasma con-
centration and drug effect. The rate constant ke0 in 
the pharmacokinetic model, together with a phar-
macodynamic model (e.g. the sigmoid Emax model) 
driven by the predicted effect site concentration, al-
lows us to characterize the effect data directly to the 
plasma concentration using non-linear regression 
analysis. This step simultaneously yields estimations 
of the pharmacokinetic and pharmacodynamic vari-
ables. The exact equations for the combination of 
an effect compartment with a three-compartment 
mammillary model can be found in the literature 
[19].
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Population pharmacokinetic analysis
The pharmacokinetic characteristics of a specifi c 
drug are usually reported as mean population varia-
bles. However, it is crucial to reveal additional infor-
mation about the magnitude of variability in the 
population receiving the drug. The analysis of pooled 
data from many subjects, or summary statistics de-
rived from individual pharmacokinetic studies, are 
generally considered to be unsatisfactory methods 
for population analysis. Although this pooled approach 
will describe the observations well most of the time 
(because the objective function for the regression 
model is precisely that  —  to minimize the error be-
tween model prediction and the observed value), 
this pooled approach is ‘naïve’ and does not take into 
account specifi c population variability. Failure to ap-
preciate the magnitude of variability in the pharma-
cology of a drug can compromise fi xed dose clinical 
trials outcomes by making the drug appear less effec-
tive or more toxic [21].
Population pharmacokinetic analysis is crucial 
during every drug development as it has considera-
ble predictive value. Previously, a ‘two-stage’ approach 
was applied to characterize population variability. In 
this case, pharmacokinetic data are derived for every 
individual from the population and then population 
mean (and standard deviations) are calculated to de-
pict the population and its variability. Although re-
ported frequently in the literature, the major problem 
of the two-stage approach is that it fails to address the 
two major sources of population variability: intra- 
versus interindividual variability [22].
When obtaining multiple blood samples from var-
ious patients to calculate the population pharmaco-
kinetic model, two problems are faced. First, there is 
a random intra-individual variability resulting from 
unavoidable (small) errors in the assay method or in-
dividual variability. Secondly, there is an interindi-
vidual variability which can be defi ned as randomized 
effects (not measurable difference between individ-
uals) or fi xed effects (measurable, also defi ned as 
covariates). Even after having entered all possible 
covariates (e.g. age, weight, height, gender, body 
surface, lean body mass), randomized effects will still 
exist. To be able to reveal all possible sources and ex-
planations of population variability, sophisticated 
statistical analysis, called non-linear mixed effect model-
ling, is required. Various commercially available soft-
ware packages are able to process population data 
using such modelling [20,23–27].
Pharmacological changes resulting 
from physiological and 
pathophysiological alterations
The different pharmacokinetic processes explained 
above may be altered because of physiological and 
pathophysiological effects leading to changes in free 
concentration at the effect site, and eventually to 
alterations in drug effect. Changes in drug effect 
may also result from changes in pharmacodynamics 
such as alterations in intrinsic drug effi cacy or end 
organ sensitivity to the drug. These events make up 
the pharmacodynamics of a drug. Both pharmacoki-
netics and pharmacodynamics are susceptible to 
physiological processes and pathophysiological 
conditions. The potential impact of age, pregnancy, 
chronopharmacology, obesity and renal, liver, 
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Figure 1.5 The three-compartment 
pharmacokinetic model enlarged with 
an effect site compartment.
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circulatory and respiratory failure, head injury and 
cardiopulmonary bypass on the pharmacology of the 
drug are discussed. The examples used to illustrate 
this section focus on drugs frequently used during 
anaesthesia.
Age
With increasing age, multiple physiological and 
pathophysiological changes occur in the cerebrovas-
cular, cardiovascular, respiratory, renal and hepatic 
systems, resulting in pharmacological changes such 
as a reduction in excretion and metabolism, and an 
increased CNS sensitivity [28]. The changes may re-
sult in an increased drug effect, reduced elimination 
rate and prolonged duration of drug action. The in-
crease in body fat, reduction in muscle mass and de-
crease in total body water with age may result in an 
increase of distribution volume for lipophilic drugs, 
and decrease for hydrophilic drugs.
For most intravenous hypnotic agents, such as 
midazolam [29] and propofol [30], and for the in-
halational anaesthetic agents, the increased sensitiv-
ity with age is, at least in part, explained by altered 
pharmacodynamics. For opioids, the pharmacody-
namic involvement is not always clear. The pro-
longed opioid effect of sufentanil in elderly patients 
has been attributed to alterations in pharmacody-
namics [31], whereas for alfentanil changes in phar-
macokinetics have been suggested to account for the 
lower dose requirement in elderly patients [32]. For 
neuromuscular agents, the increased effect in the 
elderly appears to be caused by altered pharmacoki-
netics resulting in a decreased clearance because of 
an age-related decrease in renal and hepatic 
function.
Physiological changes also infl uence the pharma-
cokinetics of drugs in children [33]. The neonatal 
phase is characterized by rapid and dramatic changes 
of organ function. Changes in body composition and 
the content of plasma proteins infl uence volume of 
distribution, the drug distribution to different com-
partments and the amount of free drug in plasma. A 
decrease in extracellular fl uid space during the fi rst 
year of life infl uences distribution volume of neu-
romuscular blocking agents which are polar drugs 
whose distribution is restricted to the extracellular 
fl uid space [34]. Thus, weight-normalized doses of 
neuromuscular blocking agents yield smaller plasma 
concentrations in neonates or infants than in chil-
dren or adults. Pharmacokinetics of propofol in 
children are characterized by a larger central com-
partment volume, which is consistent with the high-
er induction dose requirement reported for children 
[35]. As a result of the immaturity of the hepatic mi-
crosomal systems there is decreased metabolism of 
agents such as diazepam, midazolam and morphine 
[33]. In the fi rst year of life, capacity of the enzymatic 
systems increase, which is accompanied by increased 
drug clearance. For remifentanil, which is metabo-
lized by tissue and plasma esterases, the opposite is 
observed, with an increased clearance in young in-
fants compared with older children and young adults 
[36]. Beyond the neonatal period, the pharmacology 
of most opioid analgesics are not markedly different 
from those of adults [37]. Maturational changes may 
also occur in pharmacodynamics (e.g. increased sen-
sitivity to neuromuscular blocking agents in younger 
patients) [34].
Pregnancy
Throughout pregnancy there are marked physiolog-
ical changes that may have a signifi cant infl uence on 
the pharmacokinetics of drugs [38]. The increased 
minute ventilation, decreased functional residual 
capacity and increased cardiac output may result in 
increased pulmonary uptake of gases, leading to 
decreased anaesthetic requirement in pregnancy. 
However, the rate of induction with inhalational an-
aesthetic agents is not necessarily faster because this 
depends on both pulmonary equilibration kinetics 
and tissue distribution kinetics. Apparent distribu-
tion volumes of drugs may increase during preg-
nancy because of the expansion of fl uid volume and 
the presence of fetal and placental tissues resulting in 
an increased elimination half-life. However, con-
trary to what one would expect, these changes in 
distribution volume are not observed with the polar 
neuromuscular relaxants, for which distribution 
volumes are unchanged during pregnancy [39]. The 
increased cardiac output may accelerate the onset of 
action of induction agents and neuromuscular block-
ers. Unbound drug fraction may increase during 
pregnancy because of reduced albumin concentra-
tion and endogenous displacing substances. With re-
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gard to metabolism, both inhibition and induction of 
enzymes have been reported during pregnancy. The 
increased thiopental clearance during pregnancy has 
been attributed to hormonal enzyme induction. He-
patic blood fl ow is thought to be unchanged during 
pregnancy, although clearance of propofol, which is 
considered blood fl ow dependent, has been reported 
to be increased during pregnancy, and increased ex-
trahepatic clearance can probably account for this 
observation. Renal plasma fl ow is increased, result-
ing in increased renal drug excretion, and the in-
creased clearance of pancuronium during caesarian 
section has been explained by the increased glomer-
ular fi ltration rate [39]. Elimination of inhalational 
anaesthetics is expected to be enhanced by the in-
creased minute ventilation. Apart from pharmacoki-
netic changes, pharmacodynamics of drugs, although 
not well investigated in pregnancy, may also be in-
fl uenced by the physiological processes occurring. 
For instance, an increased pain threshold during 
pregnancy, mediated by endorphins, may theoreti-
cally infl uence opioid effects. The prolonged apnoea 
following large doses of succinylcholine in pregnan-
cy may be explained by decreased plasma pseudo-
cholinesterases [39].
Chronopharmacology
Chronopharmacology is the infl uence of circadian 
rhythm on the pharmacology of drugs. Pharmaco-
logical parameters are infl uenced by different physi-
ological functions displaying circadian rhythm [40]. 
Information regarding circadian rhythms for general 
anaesthesia remains fragmentary. Barbiturates are 
more effective in the evening than in the morning, 
which has been explained by endogenous variation 
in hepatic drug metabolism and by diurnal changes 
in GABAergic activity. A temporal pattern in phar-
macology has also been observed for midazolam, 
with a higher clearance after an intravenous dose in 
the late afternoon than after a morning dose and a 
circadian fl uctuation in the sensitivity of the CNS. No 
data are currently available regarding circadian 
changes for propofol or etomidate. Diurnal changes 
in the effi cacy of halothane has been investigated 
and it was found that its greatest effi cacy occurred in 
the early morning, which may theoretically be ex-
plained by circadian rhythmicity in receptor activity 
as well as distribution and metabolism. Circadian 
changes in pancuronium requirements could be ex-
plained by time-dependent changes in renal elimi-
nation and cholinesterase activity. Diurnal variation 
in pain perception has been shown to be highly rele-
vant to the daily practice of pain management, lead-
ing to variations in the need for analgesics at different 
times of day.
Obesity
Obesity can signifi cantly alter the tissue distribution 
and elimination of drugs, and may necessitate modi-
fi ed loading and/or maintenance doses [41]. The al-
tered pathophysiology of the obese body can affect 
drug distribution because of changes in body compo-
sition, regional blood fl ow and binding to plasma 
proteins. In obese people, the percentage of fat per 
kilogram of total body weight is markedly increased, 
whereas that of lean tissue is reduced. Cardiac per-
formance may be impaired and tissue blood fl ow per 
gram of fat can be signifi cantly decreased. There is 
also uncertainty about the binding of drugs to plasma 
proteins in obese patients. Increased α1-acid glyco-
protein acid levels may lead to increased protein 
binding of drugs. The behaviour of molecules with 
weak or moderate lipophilicity (e.g. vecuronium, ro-
curonium) is generally rather predictable, as these 
drugs are distributed mainly in lean tissues, and 
the dosage of these drugs should be based on the 
ideal body weight. For highly lipophilic drugs (e.g. 
remifentanil), there are great discrepancies in distri-
bution in obese individuals, and the size of the distri-
bution volume is not always correlated with the 
degree of lipophilicity.
Some data suggest that the activities of hepatic cy-
tochrome P450 isoforms are altered in obesity, but 
no clear overview of drug hepatic metabolism is cur-
rently available. Pharmacokinetic studies provide 
differing data on renal function in obese patients. 
Clearance and distribution volumes of propofol have 
been correlated with total body weight in obese pa-
tients, so that the values of the elimination half-life 
in non-obese and obese individuals are similar. This 
can explain why there are no signs of drug accumu-
lation in obese patients. For sufentanil, clearance 
and distribution volume corrected per kilogram 
of total body weight were similar in obese and 
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non-obese patients, whereas for remifentanil these 
parameters were signifi cantly smaller in obese pa-
tients. Accordingly, remifentanil doses for obese pa-
tients should be based on ideal body weight.
Liver failure
The liver is the major route for elimination of a wide 
variety of drugs. Biotransformation, liver blood fl ow, 
protein binding and biliary excretion, which can all 
potentially infl uence drug pharmacokinetics, de-
pend upon the normal functioning of the liver. Im-
paired liver function may therefore lead to signifi cant 
alterations in the pharmacokinetics of many drugs, 
necessitating dosage adjustment. Most information 
about the infl uence of liver insuffi ciency on the 
pharmacokinetics of drugs comes from patients with 
hepatic cirrhosis. However, other disease conditions 
such as hypothermia, hypotension and sepsis may 
also be associated with impaired liver function. Stud-
ies show that more than 50% of critically ill patients 
have hepatic dysfunction.
In order to fully understand the impact of liver fail-
ure on the pharmacokinetics of a particular drug, the 
underlying determinants of hepatic drug clearance 
must be well understood (see above). Measurement 
of endogenous substances such as bilirubin, bile pig-
ments, albumin and enzymes have been used to as-
sess liver function. However, unlike the assessment 
of renal function by measuring creatinine clearance, 
these parameters have not proven to be generally 
useful. Liver function tests do not generally correlate 
well with important physiological determinants of 
drug disposition such as liver blood fl ow and intrinsic 
clearance.
The histopathological changes occurring in liver 
cirrhosis are associated with a reduction in liver 
blood fl ow, the presence of portosystemic shunting 
and a reduction in the number and in the activity of 
the hepatocytes. The clinical manifestations of cir-
rhosis such as varices, oedema and ascites may also 
contribute to alterations in the pharmacokinetic be-
haviour of many drugs [42]. Impaired albumin pro-
duction in cirrhotic patients may reduce plasma 
binding and thus increase the free drug fraction. In 
addition, drug absorption may be markedly altered 
in cirrhosis. A decrease in the fraction of the me-
senteric blood fl ow passing through the liver (due to 
portosystemic shunts) and decreased activity of drug 
metabolizing enzymes may result in an increased 
bioavailability of some orally administered drugs, 
such as midazolam and morphine. Drug distribution 
of certain drugs in cirrhotic patients may be increased 
because of reduced plasma protein levels and 
changes in body composition (ascites, oedema). An 
increased distribution volume of rocuronium in 
patients with liver disease results in a longer elimina-
tion half-life and a prolonged recovery time [43]. 
Hepatic clearance of high extraction drugs in cirrhot-
ic patients is expected to be decreased because of im-
paired hepatic blood fl ow resulting from extra- and 
intrahepatic shunts. Morphine clearance was found 
to be decreased in cirrhosis [44]. However, contrary 
to what one would expect, there was no reduction in 
clearance of the high extraction drugs propofol 
[45,46], fentanyl and sufentanil [47] in cirrhotic pa-
tients. Clearance of low extraction drugs may be im-
paired because of hepatocellular damage, whereas 
an increase in free drug fraction may facilitate 
hepatic clearance of these drugs. Oxidative metabol-
ic reactions, catalysed by CYP enzymes, appear to be 
more affected than glucuronidation in cirrhotic pa-
tients; reduced oxidation of alfentanil in patients 
with cirrhosis resulted in a decreased clearance [48]. 
Reduced midazolam clearance in cirrhotic patients 
was also observed [49], which may be explained by a 
reduced CYP3A4 isoenzyme activity. The pharma-
cokinetics of remifentanil, which is metabolized by 
tissue and plasma esterases, appear to be unaffected 
in liver disease [48]. In liver cirrhosis, extrahepatic 
metabolism may compensate, at least in part, for the 
impaired metabolism of the drug by hepatic en-
zymes. Biliary obstruction in liver cirrhosis may also 
lead to impaired biliary excretion of drugs and/or 
their metabolites.
Cardiovascular failure, resulting from, for in-
stance, sepsis, cardiogenic and hypovolaemic shock, 
may also affect hepatic clearance [50–53]. In-
adequate hepatic perfusion during cardiovascular 
failure is expected to decrease clearance of high ex-
traction drugs, as has been shown for morphine in 
septic shock patients. Respiratory failure, requiring 
mechanical ventilation, often develops during car-
diovascular failure. The reduction in cardiac output 
and liver blood fl ow induced by mechanical ventila-
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tion is also expected to decrease clearance of high 
extraction drugs. The use of vasopressor agents 
may also alter hepatic blood fl ow, thereby infl uen-
cing drug clearance. Hepatocellular enzyme activity 
is often reduced during cardiovascular failure, lead-
ing to decreased clearance of low extraction drugs, 
and is presumably infl uenced by factors such as 
organ perfusion, intracellular oxygen tension and 
cofactor availability. The CYP enzyme system has 
been shown to be markedly altered in critical ill-
nesses, and to a greater extent than the phase II en-
zymes. This may be because the CYP enzyme system 
is located in the more hypoxic central region of the 
liver lobule and therefore is more sensitive to hypox-
ia. Hypoxaemia results in reduced enzyme produc-
tion in the liver, reduced effi ciency of the enzyme 
present and decreased oxygen available for drug oxi-
dation. Exposure of isolated human hepatocytes to 
hypoxia for several days resulted in a reduction in 
the CYP enzymes, with certain CYP families more af-
fected than others. In patients with congestive heart 
failure, clearance of antipyrine was reduced; this is 
a low extraction drug independent of hepatic blood 
fl ow, often used as a model substrate for microsomal 
oxidative metabolism [54]. Clearance of midazolam 
was also found to be decreased in these patients [55]. 
Hepatic drug metabolism in sepsis may also be 
reduced by the nitric oxide mediated inhibition of 
CYP-dependent drug metabolism. In vitro experi-
ments using human hepatocytes showed that cy-
tokines may also reduce CYP expression. Temporary 
failure of midazolam metabolism in patients with 
sepsis, attributed to changes in hepatic blood fl ow 
and/or hepatic enzyme activity, has been reported 
[56]. Interestingly, serum from septic patients de-
creased CYP3A4-mediated metabolism of mida-
zolam in vitro, which has been attributed to the 
depressant effects of cytokines.
Renal failure
The kidneys are responsible for the excretion of 
many drugs, both the parent drug and its metabo-
lites. The urinary excretion of a drug is the net result 
of fi ltration, secretion and reabsorption. The causes 
of renal impairment are numerous and can be 
divided into prerenal, renal and postrenal causes. 
Septic shock, for instance, initially results in a prere-
nal type of acute renal failure, which then leads to 
the full picture of tubular/obstructive acute renal 
failure. In renal failure, both the parent drug and 
metabolites may accumulate.
Renal failure may also infl uence drug distribution 
[52]. A decrease in albumin concentration, changes 
in albumin structure, and competition between en-
dogenous substances and drugs at albumin binding 
sites may increase free drug fraction during renal 
failure. This may theoretically increase drug effect 
for intravenously administered high extraction drugs 
extensively bound to albumin, and drug distribution 
volume. Both distribution volume and clearance of 
midazolam were found to be increased in patients 
with chronic renal failure, which has been attributed 
to reduced protein binding and a higher free drug 
fraction [57]. Metabolic acidosis occurring during 
renal failure may also be expected to affect drug dis-
tribution. For drugs that are weak acids, a decrease in 
pH will result in an increase in the non-ionized frac-
tion, which may theoretically enhance drug distri-
bution, whereas for weak bases the opposite may 
occur. Fluid retention is also a feature of renal fail-
ure, resulting in changes in total body water and the 
distribution of many drugs.
The kidneys have a modest capacity for autoregu-
lation, and when renal blood fl ow is moderately 
reduced (10–20%), the glomerular fi ltration rate 
does not fall. Further reductions in blood fl ow re-
sulting from, for example, cardiovascular failure, 
may compromise kidney perfusion as part of homeo-
s tasis, resulting in decreased glomerular fi ltration 
and a reduction in renal drug clearance. Clearance 
of drugs that are only fi ltered and not secreted or 
reabsorbed, is determined by both glomerular 
fi ltration rate and the free drug fraction. The phar-
macokinetics of morphine and its glucuronide 
metabolites, morphine-3-glucuronide and mor-
phine-6-glucuronide, have been investigated in in-
tensive care patients with renal failure [58]. The two 
metabolites are eliminated by renal fi ltration only, 
and a linear relationship between renal function and 
the renal clearances of the two metabolites was 
found. Renal failure may thus result in higher plas-
ma concentrations of these active metabolites. The 
latter was confi rmed in another study in which the 
increased susceptibility to morphine in patients with 
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renal failure was explained by the observed accu-
mulation of the active metabolite morphine-
6-glucuronide in cerebrospinal fl uid. The 
pharmacokinetics of the synthetic opioids alfentanil, 
sufentanil and remifentanil have been found to be 
little changed in patients with renal failure whereas 
continuous administration of fentanyl, although 
primarily metabolized in the liver, was found to re-
sult in prolonged sedation [59]. Prolonged sedation 
has also been observed after administration of mida-
zolam in critically ill patients with renal failure, 
which has been attributed to accumulation of the 
active conjugate metabolite. No changes in pharma-
cokinetics of propofol, which is mainly metabolized 
in the liver, were found in patients with end-stage 
renal disease [60]. One study even found higher 
propofol requirements in patients with end-stage 
renal disease, which has been attributed to the hy-
perdynamic circulation caused by anaemia in these 
patients [61]. In patients with chronic renal failure, 
plasma clearance of vecuronium, which mainly un-
dergoes hepatic elimination [62] resulting in an ac-
tive metabolite, was found to be decreased. Also for 
rapacuronium [63], pancuronium and their potent 
metabolites, decreased clearance was observed in 
patients with renal failure. However, pharmacoki-
netics of atracurium were found to be unaffected by 
renal failure, explained by its spontaneous chemical 
degradation and ester hydrolysis. However, concern 
has been expressed about possible accumulation of 
its principal metabolite laudanosine in patients with 
renal failure. Renal failure was found to have little 
impact on the duration of action of rocuronium and 
cisatracurium [64]. Besides renal fi ltration, urinary 
drug secretion may also be part of the renal excre-
tion process for certain drugs. Urinary drug secretion 
may be infl uenced by protein binding, depending on 
the effi ciency of the secretion process, and on the 
contact time at the secretory sites. By analogy with 
hepatic metabolism, drugs that are almost complete-
ly removed from blood within the time they are in 
contact with the active transport site, secretion is de-
pendent on blood fl ow but independent of protein 
binding, and reduced renal blood fl ow may be ex-
pected to slow elimination.
Tubular reabsorption may also occur with certain 
drugs. During cardiovascular failure, reabsorption 
may be expected to increase as a consequence of 
decreased urine fl ow accompanying a decrease in 
glomerular fi ltration rate, but documentation of 
clinically important decreases in drug excretion as a 
result of this mechanism is lacking.
Circulatory failure
Circulatory failure caused by, for example, sepsis, 
cardiac failure or haemorrhage, is a common cause 
of altered pharmacokinetics [50–53,65,66]. A dra-
matic illustration of the impact of haemorrhage on 
the pharmacology of anaesthetics has been provided 
by Halford [67], who, in 1943, described an increased 
mortality rate in wounded military personnel during 
surgery under thiopental anaesthesia at the begin-
ning of the Second World War. Regardless of aetiol-
ogy, circulatory failure results in a redistribution of 
cardiac output with blood shunted away from less 
vital organs such as kidneys, spleen and gut to vital 
organs such as heart and brain. This may result in a 
disproportionate fraction of the available cardiac 
output delivered to the heart and brain. These 
changes in blood fl ow during haemodynamic shock 
may theoretically be expected to infl uence the 
pharmacokinetics of a drug by affecting absorption, 
distribution, metabolism and excretion. The phar-
macodynamics may also be altered by changes in, for 
example, end organ sensitivity.
Circulatory dysfunction results in a decreased 
perfusion of muscles, skin and splanchnic organs. 
Absorption of drugs from sites with impaired blood 
fl ow is slow, sometimes incomplete, and subject to 
changes in circulatory status. Thus, the oral, transder-
mal, subcutaneous and intramuscular routes may 
not be reliable in critically ill patients, and an intra-
vascular route is preferred. Cardiovascular failure 
will indeed result in a reduced enteral absorption of 
drugs not only because of the decreased forward 
fl ow (reduced organ perfusion), but also because of 
the increased back pressure (venous congestion) 
in the gut circulation. Gut hypoperfusion and poor 
absorption of drugs may theoretically also be wors-
ened by mucosal oedema caused by hypoprote-
inaemia. Moreover, gastrointestinal failure is often 
present in the critically ill patient because of gut 
hypomotility (e.g. after surgery) caused by the con-
stellation of organ failure associated with sepsis or 
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as a result of the administration of opioids for 
analgesia.
The rate and extent of distribution of a drug is de-
termined by cardiac output, regional blood fl ow, the 
drug permeability of the tissue membranes and the 
relative distribution of the drug between tissue and 
blood. The latter is dependent on the binding of the 
drug in blood and tissues, the tissue mass, the lipid 
solubility of the drug and, for ionizable drugs, the 
pKa and the pH of the environment. All these deter-
minants of distribution may change during circula-
tory failure, thereby altering the drug distribution 
volume.
Cardiovascular failure with a reduction of cardiac 
output may result in decreased drug distribution re-
sulting in the homeostatic redistribution of blood 
fl ow away from less vital organs with preservation of 
blood fl ow to heart and brain. This phenomenon 
may be important for rapidly intravenously adminis-
tered drugs with a high degree of lipid solubility, such 
as anaesthetics, and may result in an increased risk of 
CNS effects. Benowitz et al. [68] illustrated this prin-
ciple by using a computer simulation of lidocaine ki-
netics for a 70-kg person in normal and hypovolaemic 
conditions following simulated removal of 30% of 
the blood volume. Following lidocaine administra-
tion, the amount of drug in the blood pool is higher 
during haemorrhage because the blood volume is 
smaller and because perfusion of other tissues is de-
creased. As a result of the higher blood concentra-
tions and the autoregulation of brain blood fl ow, 
lidocaine content in the brain is much higher in early 
phases, explaining why CNS toxicity may result 
when standard lidocaine doses are administered to 
patients with circulatory failure. The slower and de-
creased distribution of lidocaine to the muscles dur-
ing haemorrhage results from the homoeostatic 
vasoconstriction in this organ.
Systemic infl ammatory response syndrome has a 
widespread effect on the endothelium leading to 
increased capillary permeability which may result 
in accumulation of fl uids in the interstitial space. 
This so-called ‘third spacing’ phenomenon may af-
fect the distribution of drugs, particularly those with 
a small distribution volume. Endothelial barrier dis-
ruption may also lead to leakage of proteins away 
from the blood pool thereby infl uencing drug distri-
bution. Sepsis may also be expected to infl uence 
other tissue membranes, and meningeal infl amma-
tion, for instance, has been shown to increase the 
permeability of the blood–brain barrier. This is im-
portant for hydrophilic drugs, whereas penetration 
of more lipophilic compounds was found to be less 
dependent on the function of the blood–brain 
barrier.
Changes in the plasma protein binding of drugs 
during circulatory failure may be caused by changes 
in the concentration of the plasma proteins to which 
they are bound, by competition of endogenous sub-
stances for binding sites or by changes in the binding 
characteristics. Critical illness can cause increased 
concentrations of acute phase reactant proteins like 
α1-acid glycoprotein which is a major binding pro-
tein for basic drugs such as alfentanil. Increases in the 
concentration of α1-acid glycoprotein will decrease 
the unbound fraction of drugs that bind to this pro-
tein in the plasma, and result in a decreased distribu-
tion volume. In contrast, reduction in the level of 
serum albumin during critical illness because of re-
duced dietary protein intake, increased capillary per-
meability, haemodilution, renal loss and/or reduced 
hepatic synthesis may increase the free drug fraction 
of drugs that bind to albumin resulting in an in-
creased distribution volume. For midazolam, which 
is extensively bound to albumin, a negative correla-
tion was found between its distribution volume and 
the plasma albumin concentration in intensive care 
patients [69].
Fluid retention, as part of the homeostasis in 
response to a failing heart and as a result of fl uids 
administered during resuscitation, may increase the 
volume of distribution. Alterations in dis tribution 
volume may also be expected from changes in 
tissue volume. Changes in general lean body mass 
and total body fat are likely to be of importance for 
the drug distribution volume. For instance, total 
body fat will decrease during sepsis because of stimu-
lation of lipolysis and reduction of lipogenesis.
Reduced organ perfusion causes anaerobic metab-
olism and metabolic acidosis which may alter the dis-
tribution of ionizable drugs. The latter may also result 
from pH changes resulting from respiratory and kid-
ney failure. No data are available on the infl uence 
of changes in pH on drug distribution during 
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circulat ory failure. For drugs that are weak acids, a 
decrease in pH will result in an increase in the non-
ionized fraction, which may theoretically enhance 
drug distribution, whereas for weak bases the oppo-
site may occur.
Respiratory failure
Respiratory disorders induce several pathophy-
siological changes involving gas exchange and 
acid–base balance, regional haemodynamics, and al-
terations of the alveolar-capillary membrane which 
may affect absorption, distribution and elimination 
of drugs [70]. Changes in blood pH are expected to 
alter plasma protein binding and volume of distribu-
tion. Decreased cardiac output and hepatic blood 
fl ow in patients resulting from right ventricular fail-
ure or mechanical ventilation are expected to cause 
an increase in the plasma concentration of drugs 
with a high hepatic extraction ratio (see above). The 
same mechanisms may be responsible for a decreased 
renal elimination of drugs during respiratory failure. 
Acute and chronic lung disease can result in hypoxia, 
which may have signifi cant effects on the enzymes 
responsible, leading to decreased biotransformation 
of drugs with a low extraction ratio [51]. However, 
clinical data on the effects of lung disease on the 
clearance of drugs are lacking.
Head injury
Patients with head injury may develop profound 
metabolic changes resulting in a hypermetabolic, 
hypercatabolic and hyperdynamic state. These 
changes may be expected to alter pharmacokinetics. 
Hepatic oxidative and conjugative metabolism have 
indeed been shown to be signifi cantly increased 
over time in patients after acute head injury [71], re-
sulting in increased metabolism of, for instance, 
pentobarbital, thiopental and lorazepam [72]. Hy-
poalbuminaemia and a rise in α1-acid glycoprotein 
accompanying the acute phase response in patients 
with head injury are expected to alter both drug dis-
tribution and metabolism.
Cardiopulmonary bypass
Cardiopulmonary bypass is accompanied by pro-
found changes that may alter the pharmacokinetics 
of drugs [73,74]. For many drugs, such as mida-
zolam, propofol, etomidate, pancuronium, fentanyl, 
alfentanil and sufentanil, an abrupt decrease in 
serum concentration has been observed upon initia-
tion of bypass which is explained by haemodilution 
and an increase in distribution resulting from de-
creased protein binding. For opiates, adsorption to 
the bypass apparatus was shown to be important. 
The gradual increase in serum concentrations seen 
during cardiopulmonary bypass after the initial fall 
as has been observed for midazolam, etomidate and 
sufentanil is usually explained by redistribution of 
the drug from tissues to the serum and/or a decrease 
in its elimination. The latter can be caused by impair-
ment of renal or hepatic clearance resulting from 
lowered perfusion and hypothermia. The same phe-
nomena are thought to explain why in the post-by-
pass period a concentration increase occurs, or at 
least a slower decrease than expected; this has been 
observed for drugs such as midazolam, etomidate 
and fentanyl.
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